# Argenx Se (ARGX)

Source page: https://stoqly.net/companies/argx

- **Ticker:** ARGX (Nasdaq)
- **Sector:** Health Care / Biological Products, (No Diagnostic Substances)
- **SEC CIK:** 0001697862
- **Latest annual report:** 20-F filed 2026-03-19 (https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $892.87 on 2026-10-30
- **Market cap:** $59.0B
- **P/E (trailing):** 45.6x
- **EPS, trailing 12 months:** $19.57
- **Revenue (FY2025):** $4.2B
- **Revenue growth:** +88.6%
- **Revenue growth, 5-year CAGR:** +152.7%
- **Gross margin:** 89.4%
- **Operating margin:** 24.8%
- **Net margin:** 30.4%
- **Free cash flow:** $679M
- **Free cash flow margin:** 16.0%
- **Return on equity:** 20.2%
- **Change in share count:** +1.3%
- **Piotroski F-score:** 4/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/argx/figures.csv

| US$ millions | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 21 | 78 | 41 | 497 | 10 | 36 | 2,252 | 4,248 |
| Operating income | -82 | -199 | -478 | -349 | -720 | -425 | -22 | 1,054 |
| Net income | -67 | -181 | -608 | -408 | -710 | -295 | 833 | 1,292 |
| Diluted EPS (US$) | — | -4.69 | -13.40 | -7.99 | -13.05 | -5.16 | 12.78 | 19.57 |
| Operating cash flow | — | 152 | -398 | -607 | -863 | -420 | -83 | 685 |
| Free cash flow | — | 150 | -400 | -610 | -864 | -421 | -85 | 679 |
| Cash | 322 | 372 | 1,217 | 1,335 | 801 | 2,049 | 1,500 | 3,491 |
| Debt and leases | — | — | — | — | — | 7 | — | — |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.